Assessment of Cardiovascular outcomes in COVID-19 infected patients: A retrospective cohort study
Not Applicable
- Conditions
- Health Condition 1: U071- COVID 19 virus identified
- Registration Number
- CTRI/2024/04/066066
- Lead Sponsor
- I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients Above 18 Years or above are included in the study
Patients with confirmed positive SARS-CoV-2 test result and existing cardiovascular disease hospitalized between 1st January 2021 to 31st December 2022
Exclusion Criteria
Incomplete patient data
Patients who experienced mortality within 24 hours of admission
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the cardiovascular Hospitalization/Mortality in COVID 19 patientsTimepoint: 3 OCTOBER 2023 TO 5 JULY 2025
- Secondary Outcome Measures
Name Time Method To assess the prevalence of Arterial thrombosis & venous thromboembolic events <br/ ><br>To study the cardiovascular drug utilization <br/ ><br>To study the drug interactionsTimepoint: 3 OCTOBER 2023 TO 5 JULY 2025